Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
This first U.S. approval, with a REMS-restricted but flexible dosing label and no routine drug–drug interaction monitoring, marks a major shift as Cytokinetics transitions from a development-stage biotech to a commercial cardiovascular drug company. Next, we'll examine how MYQORZO's first U.S. approval for obstructive hypertrophic cardiomyopathy could reshape Cytokinetics' investment narrative and risk profile. AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. To own Cytokinetics today, you need to believe aficamten can anchor a sustainable, global HCM franchise as the company shifts from R&D heavy losses to commercial execution. The first U.S. approval for MYQORZO reduces regulatory uncertainty for obstructive HCM, but keeps commercial uptake and competitive pressure as the key near term catalyst and the biggest risk,
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Needham & Company LLC from $72.00 to $84.00. They now have a "buy" rating on the stock.MarketBeat
- Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Citizens Jmp from $78.00 to $88.00. They now have a "market outperform" rating on the stock.MarketBeat
- Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 12/19/25 - Form 8-K
- 12/16/25 - Form 4
- 12/12/25 - Form 8-K
- CYTK's page on the SEC website